STOCKS TELEGRAPH

Tag: NBRV stock

  • What’s the latest about Nabriva Therapeutics (NBRV)?

    What’s the latest about Nabriva Therapeutics (NBRV)?

    Nabriva Therapeutics (NBRV) stock is surging in the pre-market on Wednesday, March 17, 2021. It has gained 17.19% as of this writing. The stock went down 8.57% on Tuesday, March 16, 2021.

    Latest Development

    On March 16, 2021,Nabriva Therapeutics announced its results from a post-hoc analysis of clinical data from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 clinical trial has been published in The Journal of Emergency Medicine 

    The trial results revealed that the patients avoided hospitalization by taking XENLETA for 5 days. XENLETA was demonstrated in patients with moderate to severe community-acquired bacterial pneumonia (CABP). XENTLETA was approved by the FDA in August 2019 and the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly two decades.

    Recent Financial results

    On March 12, 2021, NBRV announced its financial results for the fourth quarter and the year ended December 31, 2020.

    Q4 Financial Highlights

    • NBRV revenue for the reported quarter was $2.5 million.
    • Research and development expenses were $2.8 million
    • Selling, general and administrative expense were $17.5 million

    Full-year Financial Highlights

    • NBRV revenue for the full-year 2020 was $5.0 million.
    • Research and development expenses were $15.1 million for the full year.
    • Selling, general and administrative expense were $55.3 million.
    • Nabriva had $41.4 million in cash and cash equivalents as of December 31 2020.

    NBRV Corporate Updates

    • On March 10, 2021, Steven Gelone, Pharm D, was selected by Nabriva’s Board as a new member to the board effective immediately.
    • On February 26, 2021, Daniel Dolan was appointed as Chief Financial Officer, he started working as CFO on March 13.

    NBRV Business Updates

    On March 1, 2021, Nabriva signed an agreement with investors for the purchase and sale of ordinary sharesfor aggregate net proceeds of $23.4 million.

    About NBRV

    Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. The company was founded in 2005 and is based in Ireland.

    The NBRV latest product XENLETAreceived U.S. Food and Drug Administration approval to treat CABP. The company is also working on also developing CONTEPO to treat urinary tract infections (cUTI), including acute pyelonephritis.

  • Why Nabriva Therape Ads (NBRV) stock plummeted in the after-hours trading?

    Why Nabriva Therape Ads (NBRV) stock plummeted in the after-hours trading?

    Nabriva Therape Ads (NBRV), shares price dropped -15% to $2.89 in the after-market sessionas a biopharmaceutical company specializing in the development andcommercialization of new antibiotics for treatment of serious infections,announced the pricing of its public offering of 6,000,000 ordinary shares at a price of $2.50 per share (or pre-funded warrant).

    In connection with this offering, H.C. Wainwright & Co. serves as the exclusive placement agent. Northland Securities, Inc. provides the financial advisory services. Before the placement agent’s fees and other estimated offering expenses payable by Nabriva Therapeutics, the gross proceeds from the offering are $15 million.

    Providing customary closing conditions are satisfied, the offering is expected to close by December 15, 2020.

  • Nabriva Therapeutics AG (NBRV) plunged following the announcement of a reverse share split

    Nabriva Therapeutics AG (NBRV) plunged following the announcement of a reverse share split

    Nabriva Therapeutics AG (NBRV) stock slid 2.49% to 3.850 in the early trading session following the announcement of the Company that it will divide its outstanding ordinary shares into 1-for-10 reverse shares, applicable for trading purposes on the Nasdaq Global Select Market as of the beginning of trading on the Nasdaq Global Select Market.

    At the Yearly Shareholders’ meeting on 29 July 2020, the shareholders of Nabriva Therapeutics agreed, before and subject to the decision by the Board of Directors of Nabriva Therapeutics, in its absolute discretion, that a reverse share split is necessary for the Company to comply with a minimum requirement of $1.00 per share under Nasdaq Listing Regulation 5450(a)(1) (Bid Price Rule).

    Every ten ordinary shares of $0.01 each of the Company authorized and unissued, authorized and approved share capital shall be combined into one ordinary share of $0.10 each, thus reducing the nominal value of the ordinary shares of the Company’s authorized and unissued, authorized and issued share capital from $0.10 each to $0.01 each. The Board of Directors of Nabriva Therapeutics then decided that the reverse stock split was appropriate for the Company to conform with the Bid Price Law.

    The ordinary shares of Nabriva Therapeutics will continue to trade under the name ‘NBRV’ on the Nasdaq Global Select Market. The current CUSIP number for the ordinary shares of Nabriva Therapeutics after the reverse stock split is G63637 113.

    The reverse stock split would decrease outstanding ordinary shares from approximately 150,8 million to about 15,08 million post-split shares. It will also minimize the number of outstanding ordinary shares from 1,0 billion to 100,0 million in proportion.

    The reverse stock split will also refer to ordinary shares issued when the remaining limited stock units, stock options, and warrants of Nabriva Therapeutics are exercised, with a proportionate rise, if appropriate, in the corresponding exercise prices.

    In conjunction with the reverse stock split, no ordinary fractional shares will be issued. Shareholders who would generally be entitled to accept a proportional cash bonus would be entitled to receive an ordinary fractional share.

  • 41 Stocks Taking Bigger Strides in Pre-Market Session

    41 Stocks Taking Bigger Strides in Pre-Market Session

    IMAC Holdings Inc. (IMAC) stock plunged -13.16% to $1.32 in the pre-market trading after the company reported third-quarter earnings. The most recent rating by Ascendiant Capital Markets, on April 15, 2020, is at a Buy.

    Allied Healthcare Products Inc. (NASDAQ: AHPI) shares are trading down -10.31% at $7.05 at the time of writing. The company’s 52-week range was noted as $0.92 to $45.00.

    EuroDry Ltd. (EDRY) tumbled over -16.9% at $5.9 in pre-market trading today following Company posted results for the nine-month period and quarter ending September 30, 2020.

    Pyxis Tankers Inc. (PXS), a Marine Shipping company, dropped about -11.86% at $1.04 in pre-market trading Friday as a result of publication stating announcement date of quarterly results and conferencing call.

    XPeng Inc. (XPEV) stock moved up 5.41 percent to $47.15 in the pre-market trading after the news that it has posted strong operating and financial results as a public company.

    Electra Meccanica Vehicles Corp. (SOLO) gained over 18.01% at $5.7 in pre-market trading Friday 13 November 2020 as the company posted robust 3rd quarter results.

    Li Auto Inc. (LI) is up more than 19.57% at $38.0 in pre-market hours Friday 13 November 2020 as the news appeared that the company has announced unaudited Q3 earnings. The stock had jumped over 27.27% to $31.78 in the last trading session.

    Before the trading started on 13 November 2020, Sino-Global Shipping America Ltd. (SINO) is down -7.02% to reach $2.25 following the company revealed earnings scores of fiscal 2020. It has been trading in a 52-week range of $1.37 to $4.89.

    Biocept Inc. (BIOC) stock plunged -15.42% to $5.21 in the pre-market trading as the firm posted third-quarter earnings. The most recent rating by Chardan Capital Markets, on November 14, 2017, is at a Buy.

    Fulgent Genetics Inc. (NASDAQ: FLGT) shares are trading up 6.63% at $41.0 at the time of writing after the news surfaced that company has reported record 3rd quarter earnings and raised its outlook for full-year 2020. The company’s 52-week range was noted as $6.70 to $52.47. Analysts have a consensus price target of $75.

    Zhongchao Inc. (ZCMD) tumbled over -10.7% at $1.92 in pre-market trading today after it was publicized that Zhongchao Inc. and Takeda pharmaceutical will expand the extent of collaboration in China.

    CBAK Energy Technology Inc. (CBAT), an Electrical Equipment & Parts company, rose about 28.46% at $5.1 in pre-market trading.

    Aeterna Zentaris Inc. (AEZS) lost over -11.11% at $0.32 in pre-market trading Friday 13 November 2020 as it was reported that the giant has announced its 3rd quarter earnings results as well provided business update.

    Northern Dynasty Minerals Ltd. (NAK) is down more than -4.5% at $0.885 in pre-market hours Friday 13 November 2020. The stock had jumped over 13.08% to $0.93 in the last trading session.

    Before the trading started on 13 November 2020, 9F Inc. (JFU) is down -9.68% to reach $1.12. It has been trading in a 52-week range of $0.72 to $11.41.

    Boxlight Corporation (BOXL) stock soared 4.97% to $1.69 in the pre-market trading after the news that the company is set to hold data for its Q3 earnings results and conference call. The most recent rating by National Securities, on May 19, 2020, is at a Buy.

    CureVac N.V. (NASDAQ: CVAC) shares are trading up 5.83% at $73.75 at the time of writing as cureVac’s COVID-19 vaccine candidate, CVnCoV, is suitable for standard fridge temperature Logistics. The company’s 52-week range was noted as $36.15 to $85.00.

    NIO Limited (NIO) grew over 5.57% at $50.99 in pre-market trading today as the news surfaced that the Chinese maker of electric vehicles, Nio Inc (NASDAQ: NIO), is facing intensified competition from Tesla Inc (NASDAQ: TSLA), which will only get more serious with the introduction of its China-made Model Y car.

    Revlon Inc. (REV), a Household & Personal Products company, dropped about -8.49% at $11.0 in pre-market trading Friday after the reports that company sales dropped during the third fiscal quarter.

    Kandi Technologies Group Inc. (KNDI) stock moved up 12.72 percent to $7.8 in the pre-market trading after it was revealed in the news that Kandi Technologies announced the closing of a registered direct placement of $60 million of common stock and warrants.

    Niu Technologies (NIU) gained over 4.49% at $33.29 in pre-market trading Friday 13 November 2020 as it was reported the company will announce its quarterly results on November 23, 2020.

    Onconova Therapeutics Inc. (ONTX) is down more than -10.86% at $0.2601 in pre-market hours Friday 13 November 2020 as news appeared that the company has issued a business update and reveled its quarterly earnings results. The stock had jumped over 7.99% to $0.29 in the last trading session.

    Before the trading started on 13 November 2020, Futu Holdings Limited (FUTU) is up 4.7% to reach $41.68 as it was publicized that the company’s stock will be added to the MSCI Hong Kong Small Cap Index. It has been trading in a 52-week range of $8.16 to $40.99.

    Fisker Inc. (FSR) stock soared 5.86% to $15.89 in pre-market trading. The most recent rating by Cowen, on November 09, 2020, is at an Outperform.

    Novavax Inc. (NASDAQ: NVAX) shares are trading up 5.43% at $95.8 at the time of writing. The company’s 52-week range was noted as $3.54 to $189.40 after the report that company loss widened in Q3 and revenues missed analysts’ estimates. Analysts have a consensus price target of $290.

    Kaixin Auto Holdings (KXIN) grew over 9.46% at $3.47 in pre-market trading today.

    Vipshop Holdings Limited (VIPS), an Internet Retail company, rose about 6.09% at $23.5 in pre-market trading Friday after the exciting news surfaced that the stock earnings beat analysts’ predictions.

    Inovio Pharmaceuticals Inc. (INO) stock moved up 4.75 percent to $11.9 in the pre-market trading after the company posted its third-quarter results.

    Fastly Inc. (FSLY) gained over 4.94% at $80.01 in pre-market trading Friday 13 November 2020.

    Verastem Inc. (VSTM) is up more than 4.64% at $1.58 in pre-market hours Friday 13 November 2020 after the company highlighted its recent progress along with its quarterly results. The stock had jumped over 5.59% to $1.51 in the last trading session.

    Before the trading started on 13 November 2020, NovaBay Pharmaceuticals Inc. (NBY) is down -19.99% to reach $0.52 as the company posted Q3 earnings reports. It has been trading in a 52-week range of $0.24 to $1.94.

    Digital Ally Inc. (DGLY) stock plunged -7.51% to $2.34 in the pre-market trading after the publication of the company’s Q3 operating results. The most recent rating by Aegis Capital, on June 29, 2020, is at a Buy.

    Jumia Technologies AG (NYSE: JMIA) shares are trading up 5.01% at $14.25 at the time of writing after the company said that it has managed to cut down on losses after making a strategic shift due to covid-19. The company’s 52-week range was noted as $2.15 to $23.90. Analysts have a consensus price target of $4.50.

    JD.com Inc. (JD) grew over 4.83% at $90.55 in pre-market trading today after the company revealed the date of its earnings call.

    Creative Realities Inc. (CREX), a Software – Application company, dropped about -15.53% at $0.87 in pre-market trading Friday as the company reported its third-quarter 2020 results.

    Myovant Sciences Ltd. (MYOV) stock moved up 6.43 percent to $18.22 in the pre-market trading following Corporate Updates and Financial Results for the second-quarter fiscal year 2020.

    Cassava Sciences Inc. (SAVA) lost over -19.59% at $8.99 in pre-market trading Friday 13 November 2020 as Cassava Sciences announced a proposed public offering of common stock.

    Four Seasons Education (Cayman) Inc. (FEDU) is down more than -6.41% at $0.82 in pre-market hours Friday 13 November 2020. The stock had jumped over 2.82% to $0.88 in the last trading session.

    Before the trading started on 13 November 2020, Bionano Genomics Inc. (BNGO) is down -6.65% to reach $0.535 as the company revealed its latest business update along with quarterly earnings results. It has been trading in a 52-week range of $0.25 to $1.39.

    Blink Charging Co. (BLNK) stock plunged -5.94% to $9.82 in the pre-market trading as the company revealed both quarterly and nine-month 2020 results. The most recent rating by H.C. Wainwright, on August 14, 2020, is at a Neutral.

    Farfetch Limited (NYSE: FTCH) shares are trading up 15.71% at $50.0 at the time of writing as the company posted Q3 earnings results. The company’s 52-week range was noted as $5.99 to $44.73. Analysts have a consensus price target of $42.

    Kensington Capital Acquisition Corp. (KCAC) grew over 11.19% at $15.9 in pre-market trading today after the company announced on November 25, 2020, a special meeting will be held to approve the business combination.

    Aytu BioScience Inc. (AYTU), a Biotechnology company, dropped about -2.93% at $0.9998 in pre-market trading Friday following Aytu BioScience announced fiscal Q1 2021 net revenue of $13.5 Million, an increase of 839% year-over-year.

    Palatin Technologies Inc. (PTN) stock moved up 4.22 percent to $0.4151 in the pre-market trading after it reports 1st quarter and fiscal year 2021 results; Teleconference and Webcast to be held on November 17, 2020.

    SPI Energy Co. Ltd. (SPI) gained over 5.43% at $8.15 in pre-market trading Friday 13 November 2020.

    Nabriva Therapeutics plc (NBRV) stock soared 6.41% to $0.45 in the pre-market trading. The most recent rating by Wedbush, on March 19, 2020, is at a Neutral. Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences.

    Timber Pharmaceuticals Inc. (AMEX: TMBR) shares are trading up 5.32% at $0.99 at the time of writing after the announcement of the business update and 3rd quarter results. The company’s 52-week range was noted as $0.87 to $12.60.